{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:21:17Z","timestamp":1769851277605,"version":"3.49.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>This study aimed to investigate the association between tumor hypoxia, assessed through anti-HIF (hypoxia-inducible factor) staining, and aggressiveness in prostate cancer using a pharmacokinetic model, particularly those derived from the Tofts model, in predicting tumor aggressiveness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material and Methods:<\/jats:title>\n            <jats:p>From January 2019 to April 2021, we conducted a retrospective search of patients with confirmed prostate cancer and a previous magnetic resonance imaging (MRI) examination. After exclusions, a total of 57 consecutive patients were enrolled. Patient data, including demographic, laboratory, and pathologic variables, were collected. MRI acquisition followed PI-RADS guidelines, encompassing T2-weighted, diffusion-weighted imaging, and dynamic contrast-enhanced imaging. An experienced abdominal radiologist conducted both morphologic and quantitative MRI analyses, evaluating parameters such as lesion size, apparent diffusion coefficient values, and the Tofts pharmacokinetics (TF) model. The histopathologic analysis included the International Society of Uropathology (ISUP) score and hypoxia marker immunohistochemistry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There were no significant demographic and imaging differences between hypoxic and nonhypoxic tumors, except for elevated prostate-specific antigen levels in the latter and decreased normalized apparent diffusion coefficient in the former. Morphologic assessments revealed larger lesions in the hypoxia group. While <jats:italic toggle=\"yes\">K<\/jats:italic>\n                                 <jats:sub>trans<\/jats:sub> showed a positive association with hypoxia, it did not independently predict high-risk lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our results suggest that pharmacokinetic analysis by the Tofts model was associated with tumors with hypoxia. However, this parameter was not an independent predictor of more aggressive tumors. Further studies, with a larger number of patients, multi-institutional and prospective, are needed to verify this possible association.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rct.0000000000001707","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T01:00:17Z","timestamp":1736557217000},"page":"571-576","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pilot Study Examining the Use of DCE MRI With Pharmacokinetic Analysis to Evaluate Hypoxia in Prostate Cancer"],"prefix":"10.1097","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9458-7226","authenticated-orcid":false,"given":"Eduardo Miguel","family":"Febronio","sequence":"first","affiliation":[{"name":"Department of Imaging, Oncology and Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 de Freitas","family":"Secaf","sequence":"additional","affiliation":[{"name":"Department of Imaging, Oncology and Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Chahud","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Elias","sequence":"additional","affiliation":[{"name":"Department of Imaging, Oncology and Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo B.","family":"Reis","sequence":"additional","affiliation":[{"name":"Department of Surgery and Anatomy, Urology Division, Ribeirao Preto School of Medicin, University of Sao Paulo, Sao Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valdair F.","family":"Muglia","sequence":"additional","affiliation":[{"name":"Department of Imaging, Oncology and Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"R2-20250711","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer\u20142020 Update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"R3-20250711","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1001\/jama.291.22.2713","article-title":"Natural history of early, localized prostate cancer","volume":"291","author":"Johansson","year":"2004","journal-title":"JAMA"},{"key":"R4-20250711","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.ijrobp.2010.01.006","article-title":"Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?","volume":"79","author":"Kuban","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R5-20250711","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2011.04.027","article-title":"Impact of hypoxia on the metastatic potential of human prostate cancer cells","volume":"81","author":"Dai","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R6-20250711","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10555-007-9063-1","article-title":"Hypoxia, gene expression, and metastasis","volume":"26","author":"Chan","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"R7-20250711","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1158\/1078-0432.CCR-06-2971","article-title":"Hypoxia and metastasis","volume":"13","author":"Chaudary","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R8-20250711","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semradonc.2008.12.002","article-title":"Cancer stem cells, hypoxia and metastasis","volume":"19","author":"Hill","year":"2009","journal-title":"Semin Radiat Oncol"},{"key":"R9-20250711","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrd1199","article-title":"HIF-1 as a target for drug development","volume":"2","author":"Giaccia","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"R10-20250711","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"R11-20250711","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1470-2045(08)70076-7","article-title":"Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study","volume":"9","author":"Vergis","year":"2008","journal-title":"Lancet Oncol"},{"key":"R12-20250711","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1677\/erc.1.00728","article-title":"Hypoxia-inducible factor-1 in human breast and prostate cancer","volume":"13","author":"Kimbro","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"R13-20250711","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1158\/1078-0432.CCR-11-2711","article-title":"Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer","volume":"18","author":"Milosevic","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R14-20250711","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.2014.604","article-title":"The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer","volume":"112","author":"Ragnum","year":"2015","journal-title":"Br J Cancer"},{"key":"R15-20250711","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2005.11.044","article-title":"An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance","volume":"65","author":"Carnell","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20250711","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41585-019-0212-4","article-title":"Multiparametric MRI for prostate cancer diagnosis: current status and future directions","volume":"17","author":"Stabile","year":"2020","journal-title":"Nat Rev Urol"},{"key":"R17-20250711","doi-asserted-by":"crossref","first-page":"6940","DOI":"10.1007\/s00330-019-06166-z","article-title":"The primacy of multiparametric MRI in men with suspected prostate cancer","volume":"29","author":"Richenberg","year":"2019","journal-title":"Eur Radiol"},{"key":"R18-20250711","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2214\/AJR.12.8510","article-title":"Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management","volume":"198","author":"Verma","year":"2012","journal-title":"Am J Roentgenol"},{"key":"R19-20250711","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/crad.1999.0327","article-title":"Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA","volume":"55","author":"Padhani","year":"2000","journal-title":"Clin Radiol"},{"key":"R20-20250711","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S","article-title":"Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols","volume":"10","author":"Tofts","year":"1999","journal-title":"J Magn Reson Imaging"},{"key":"R21-20250711","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00261-018-1771-1","article-title":"Hypoenhancing prostate cancers on dynamic contrast-enhanced MRI are associated with poor outcomes in high-risk patients: results of a hypothesis generating study","volume":"44","author":"Muglia","year":"2019","journal-title":"Abdom Radiol (NY)"},{"key":"R22-20250711","doi-asserted-by":"crossref","first-page":"351","DOI":"10.21873\/anticanres.16170","article-title":"Exploring hypoxia in prostate cancer with T2-weighted magnetic resonance imaging radiomics and pimonidazole scoring","volume":"43","author":"Leech","year":"2023","journal-title":"Anticancer Res"},{"key":"R23-20250711","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"R24-20250711","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1148\/radiology.211.1.r99ap38101","article-title":"Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?","volume":"211","author":"Kuhl","year":"1999","journal-title":"Radiology"},{"key":"R25-20250711","doi-asserted-by":"crossref","first-page":"152694","DOI":"10.1016\/j.prp.2019.152694","article-title":"Immunohistochemical analysis of the impact of ischemic change in benign prostatic hyperplasia","volume":"216","author":"Jin Cho","year":"2020","journal-title":"Pathol Res Pract"},{"key":"R26-20250711","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"key":"R27-20250711","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ijrobp.2007.01.018","article-title":"Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations","volume":"68","author":"Hoskin","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R28-20250711","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.mri.2017.11.008","article-title":"Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours?","volume":"46","author":"Little","year":"2018","journal-title":"Magn Reson Imaging"},{"key":"R29-20250711","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.2214\/AJR.11.6861","article-title":"Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis","volume":"197","author":"Oto","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"R30-20250711","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1007\/s00261-017-1058-y","article-title":"Assessment of prostate cancer aggressiveness using apparent diffusion coefficient values: impact of patient race and age","volume":"42","author":"Tamada","year":"2017","journal-title":"Abdom Radiol (NY)"},{"key":"R31-20250711","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00261-016-0848-y","article-title":"The utility of quantitative ADC values for differentiating high-risk from low-risk prostate cancer: a systematic review and meta-analysis","volume":"42","author":"Shaish","year":"2017","journal-title":"Abdom Radiol (NY)"},{"key":"R32-20250711","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.eururo.2013.05.045","article-title":"Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T","volume":"64","author":"Vos","year":"2013","journal-title":"Eur Urol"},{"key":"R33-20250711","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40798-022-00436-9","article-title":"Modulating tumour hypoxia in prostate cancer through exercise: the impact of redox signalling on radiosensitivity","volume":"8","author":"Brown","year":"2022","journal-title":"Sports Med Open"}],"container-title":["Journal of Computer Assisted Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:00:14Z","timestamp":1752253214000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rct.0000000000001707","relation":{},"ISSN":["0363-8715","1532-3145"],"issn-type":[{"value":"0363-8715","type":"print"},{"value":"1532-3145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"2024-06-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}